Alchemab Therapeutics
Develops antibody therapeutics found in the immune systems of disease-resilient people, using AI on antibody repertoires.
alchemab.com ↗Why it's here
Added £25M from the British Business Bank in July 2026, taking its Series A to £109M.
source: european-biotechnology.com- Focus
- Antibody Discovery
- Founded
- 2019
- Latest round
- Series A extension, £25M, Jul 2026
- London office
- East Side, Office 1.02, Kings Cross, Camden N1C 4AXsource: alchemab.com
- London presence
- HQsource: builtinlondon.uk
- Investors
- British Business Bank, Camford Partners, DCVC Bio, Dementia Discovery Fund, Eli Lilly, Lightstone Ventures, Ono Venture Investment, RA Capital, SV Health Investorssource: european-biotechnology.com
- Area
- King's Cross
- Nearest station
- King's Cross & St Pancras International, 80 m
- Visas
- Licensed visa sponsor, listed as Alchemab Therapeutics Limitedsource: gov.uk
Verified 6 Oct 2026. How we verify · Suggest a fix
For Alchemab Therapeutics
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/alchemab-therapeutics"><img src="https://londonmempool.co.uk/badge/alchemab-therapeutics.svg" alt="Alchemab Therapeutics is listed on London Mempool" width="361" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.